Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancer

Journal of Clinical Pathology

Volumn 58, Issue 7, 2005, Pages 734-739

  Esposito, V ^b   Baldi, A ^a,c   De Luca, A ^c   Tonini, G ^d   Vincenzi, B ^d   Santini, D ^d   Persichetti, P ^d   Mancini, A ^c   Citro, G ^e   Baldi, F ^c   Groeger, A M ^a   Caputi, M ^c  

^a International Society for the Study of Comparative Oncology ^*  (Italy)

^b International Society for the Study of Comparative Oncology ISSCO   (United States)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; PROTEIN P105; PROTEIN P130; PROTEIN P16; PROTEIN P27; PROTEIN P53; REGULATOR PROTEIN; RETINOBLASTOMA PROTEIN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PARAMETER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SURVIVAL RATE; TISSUE SECTION;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; PROTEINS; RETINOBLASTOMA-LIKE PROTEIN P130; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 21844434717     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2004.023531     Document Type: Article

References (34)

1. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003;95:1258-61.
2. Fong KM, Sekido Y, Minna JD. Molecular pathogenesis of lung cancer. J Thorac Cardiovasc Surg 1999;118:1136-52.
3. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-8.
4. Esposito V, Baldi A, Tonini G, et al. Analysis of cell cycle regulator proteins in non-small cell lung cancer. J Clin Pathol 2004;57:58-63.
5. Yoshida T, Tanaka S, Mogi A, et al. The clinical significance of cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol 2004;15:252-6.
6. Cheng YL, Lee SC, Harn HJ, et al. Prognostic prediction of the immunohistochemical expression of p53 and p16 in resected non-small cell lung cancer. Eur J Cardiothorac Surg 2003;23:221-8.
7. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics. CA Cancer J Clin 2000;50:7-33.
8. Fielding LP, Fenoglio-Preiser CM, Freedman LS. The future of prognostic factors in outcome prediction for patients with cancer. Cancer 1992;70:2367-7.
9. Mountain CF. New prognostic factors in lung cancer: biologic prophets of cancer cell aggression. Chest 1995;108:246-54.
10. Niklinski J, Furman M. Clinical tumour markers in lung cancer. Eur J Cancer Prev 1995;4:129-38.
11. Gajra A, Tatum AH, Newman N, et al. The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer. Lung Cancer 2002;36:159-65.
12. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-17.
13. Zirbes TK, Baldus SE, Moenig SP, et al. Prognostic impact of p21/waf1/cip1 in colorectal cancer. Int J Cancer 2000;89:14-18.
14. Yuan J, Knorr J, Altmannsberger M, et al. Expression of p16 and lack of pRB in primary small cell lung cancer. J Pathol 1999;189:358-62.
15. Shim YH, Kang GH, Ro JY. Correlation of p16 hypermethylation with p16 protein loss in sporadic gastric carcinomas. Lab Invest 2000;80:689-95.
16. Paradiso A, Rabinovich M, Vallejo C, et al. p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis. Int J Cancer 1996;69:437-41.
17. Ishihara S, Minato K, Hoshino H, et al. The cyclin-dependent kinase inhibitor p27 as a prognostic factor in advanced non-small cell lung cancer: its immunohistochemical evaluation using biopsy specimens. Lung Cancer 1999;26:187-94.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
19. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Br J Cancer 1977;35:1-39.
20. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.
21. Zochbauer-Muller S, Gazdar AF, Minna JD. Molecular pathogenesis of lung cancer. Annu Rev Physiol 2002;64:681-708.
22. Caputi M, Esposito V, Baldi A, et al. p53-independent expression of p21 cdks inhibitor in non small cell lung cancer: relationship to survival. Am J Respir Cell Mol Biol 1998;18:213-17.
23. Mitsudomi T, Hamajima N, Ogawa M, et al. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000;6:4055-63.
24. Shoji T, Tanaka F, Takata T, et al. Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol 2002;20:3865-71.
25. Zhou JX, Niehans GA, Shar A, et al. Mechanisms of G1 checkpoint loss in resected early stage non-small cell lung cancer. Lung Cancer 2001;32:27-38.
26. Kaye FJ. RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. Oncogene 2002;21:6908-14.
27. Groeger AM, Caputi M, Esposito V, et al. Independent prognostic role of p16 expression in lung cancer. J Thorac Cardiovasc Surg 1999;118:529-35.
28. Baldi A, Esposito V, De Luca A, et al. Differential expression of the retinoblastoma gene family members, Rb/p105, p107 and Rb2/p130, in lung cancer. Clin Cancer Res 1996;2:1239-45.
29. Baldi A, Esposito V, De Luca A, et al. Differential expression of Rb2/p130 and p107 in normal human tissues and in primary lung cancer. Clin Cancer Res 1997;3:1691-7.
30. Kaye FJ. RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. Oncogene 2002;21:6908-14.
31. Esposito V, Baldi A, De Luca A, et al. Prognostic value of p53 in non small cell lung cancer: relationship with proliferating cell nuclear antigen and cigarette smoking. Hum Pathol 1997;2:233-7.
32. Mitsudomi T, Hamajima N, Ogawa M, et al. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000;6:4055-63.
33. Franklin DS, Godfrey VL, O'Brien DA, et al. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol Cell Biol 2000;20:6147-58.
34. Geradts J, Fong KM, Zimmerman PV, et al. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygositv, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res 1999;5:791-800.